Skip to main content

Table 4 Comparison of effective doses (ED) according to ICRP60 and absorbed doses to kidneys between available studies on RGD-based radiopharmaceuticals assuming 1-h voiding cycle. Mean ± SD are reported

From: First in-human radiation dosimetry of 68Ga-NODAGA-RGDyK

Radiopharmaceutical No. of patients ED ICRP60
(μSv/MBq)
Dose to kidneys
(μGy/MBq)
18F-Galacto-RGD (Beer et al.) [37] 18 18.68 ± 2.42 29.52 ± 11.95
18F-RGD-K5 (Doss et al.) [34] 4 15 ± 1 45 ± 10
18F-FPPRGD2a (Mittra et al.) [33] 5 39.6 ± 18.1 97.6 ± 50.2
68Ga-NOTA RGD (Kim et al.) [36] 10 24.98 ± 4.39 71.61 ± 28.38
68Ga-DOTA-E [cRGDfK]2a (Lopey-Rodriguez et al.) [35] 5 20.9 ± 5.1 53.8 ± 5.3b
68Ga-NODAGA-RGDyK (this study) 5b 19.3 ± 1.8b 46.4 ± 11.3b
  1. aDimeric RDG radiopharmaceuticals
  2. bValues are tabulated for male patients only